key: cord-0750001-gkgfupcw
authors: Morley, Gabriella L.; Taylor, Stephen; Jossi, Sian; Perez-Toledo, Marisol; Faustini, Sian E.; Marcial-Juarez, Edith; Shields, Adrian M.; Goodall, Margaret; Allen, Joel D.; Watanabe, Yasunori; Newby, Maddy L.; Crispin, Max; Drayson, Mark T.; Cunningham, Adam F.; Richter, Alex G.; O’Shea, Matthew K.
title: Sensitive Detection of SARS-CoV-2–Specific Antibodies in Dried Blood Spot Samples
date: 2020-12-03
journal: Emerg Infect Dis
DOI: 10.3201/eid2612.203309
sha: a20dd8cd5651cc7be26dc952b5ebc4029080e055
doc_id: 750001
cord_uid: gkgfupcw

Dried blood spot (DBS) samples can be used for the detection of severe acute respiratory syndrome coronavirus 2 spike antibodies. DBS sampling is comparable to matched serum samples with a relative 98.1% sensitivity and 100% specificity. Thus, DBS sampling offers an alternative for population-wide serologic testing in the coronavirus pandemic.

from PCR testing. All participants were anonymized, and SARS-CoV-2 PCR status was recorded as positive or unknown.

For DBS collection, we collected capillary blood samples onto forensic-grade 226 DBS cards (Ahlstrom Munksjo, https://www.ahlstrom-munksjo.com) by using finger-prick lancets (4, 8) . We stored DBS cards at room temperature in individual sample bags with desiccant. Concomitantly, we collected venous blood from volunteers and separated serum by using centrifugation at 9,700 × g for 5 min at room temperature. Laboratory analysis was blinded to PCR status, and we reported SARS-CoV-2-specific antibody results as positive, negative, or equivocal.

To elute antibody from DBS cards, we isolated individual preperforated DBS spots by using a sterile pipette tip and placed them into a universal tube at a ratio of 1 spot to 250 µL 0.05% phosphatebuffered saline (PBS)-Tween 20 (PBS-T) (PBS, xoid; Tween-20; Sigma-Aldrich, https://www.sigma aldrich.com). We briefly vortexed and incubated tubes overnight at room temperature. We then harvested DBS eluate into a microtube and centrifuged it at 10,600 × g for 10 min at room temperature. We stored eluate at 4°C for <14 days in accordance with standard protocols (4). We quantified total IgG, IgA, and IgM concentrations in matched serum and DBS eluate, plus pre-August 2019 DBS samples, with nephelometry by using the automated COBAS 6000 (Roche, https://www.roche.com).

We performed a highly sensitive and specific inhouse ELISA (now under peer review) to measure IgG, IgA and IgM against soluble, stabilized, trimeric SARS-CoV-2 spike (S) glycoprotein (9,10), as Tween-20 and BSA, Sigma-Aldrich) at starting dilutions of 1:3 DBS eluate and 1:15 serum, with 3-fold serial dilutions; or single dilutions of 1:10 DBS eluate and 1:100 serum. We diluted mouse monoclonal anti-human horseradish peroxidase conjugated antibodies (anti-IgG R-10 1:8,000, anti-IgA MG4.156 1:4,000, and anti-IgM AF6 1:2,000; Abingdon Health, https://www.abingdonhealth.com) in 0.1% PBS-T. We developed plates with TMB Core (Bio-Rad, https://www.bio-rad.com) and stopped them after 5 min with 0.2M H 2 SO 4 (Sigma-Aldrich). We recorded optical densities at 450 nm (OD 450 ) by using the Dynex Revelation (Dynex Technologies, https://www.dynextechnologies.com). We reported results as SARS-CoV-2 S antibody positive, negative, or equivocal. The cutoff for negativity was less than the highest negative control (DBS 0.399 OD 450 and serum 0.449 OD 450 ), and for positivity, the mean of the negative controls +3 SD (DBS 0.444 OD 450 and serum 0.62 OD 450 ); a result between this range was considered equivocal.

We performed statistical analyses by using Prism 8 (GraphPad, https://www.graphpad.com) and assessed correlations between continuous data by using Spearman's rank test (p<0.05 was considered statistically significant). We assessed DBS sample ELISA performance, relative to the serum assay, by calculating the comparative sensitivity, specificity, and positive and negative predictive values, with 95 % CIs.

We assessed the agreement between DBS and serum ELISA results by determining the Cohen κ coefficient and Bland-Altman mean-difference. We performed quantification of total immunoglobulin concentrations in serum and DBS eluate. We observed 7-to 11-fold reduction in mean immunoglobulin concentration (IgG, IgA, and IgM) in DBS eluate compared with matched serum (Table 1) . Matched serum and DBS titration curves showed the detection of SARS-CoV-2 S glycoprotein antibodies in both serum and DBS eluate with the limits of detection and the optimal detection dilution indicated (1:10 for DBS eluate and 1:100 for serum). PCR-positive matched samples showed higher responses, whereas pre-August 2019 DBS samples were negative across all dilutions (Figure 1 ).

We measured OD 450 detected by ELISA for matched DBS eluate (diluted 1:10) and serum (diluted Discordance occurred between only 1 matched sample (κ = 0.975). Relative to serum samples, DBS samples achieved 98.11% sensitivity and 100% specificity for detecting S glycoprotein antibodies ( Table 2) ; 100% of the PCR-positive samples (n = 31) were also antibody-positive in DBS eluate.

We show that DBS samples can be used for the detection of SARS-CoV-2-specific antibodies with results comparable to serum samples, supporting the findings of recent preliminary studies (11, 12) . Although individual laboratories should optimize DBS-derived antibody detection, considering dilution-factor and cutoff thresholds for their relevant downstream assay, these results demonstrate that DBS sampling could complement venipuncture for serologic assessments, such as seroprevalence studies, during the COVID-19 pandemic.

A current limitation of antibody assays is the necessity for venipuncture by skilled phlebotomists; DBS sampling overcomes this limitation and introduces the opportunity for wider population-level testing and improved surveillance in groups at heightened risk for infection. For example, DBS could be delivered using postal services (4) to patients with chronic conditions, the immunocompromised, and the elderly, all of which are groups disproportionately affected by CO-VID-19 (13) . Furthermore, the DBS method is simple and inexpensive (4), which could enhance sampling in low-and middle-income countries, among groups where venipuncture is culturally unacceptable or in a geographically dispersed population. 

Detection of SARS-CoV-2 in different types of clinical specimens

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study

Dried blood spot and mini-tube blood sample collection kits for postal HIV testing services: a comparative review of successes in a real-world setting

Evaluation of dried blood spot samples for screening of hepatitis C and human immunodeficiency virus in a real-world setting

Detection of immunoglobulin G to measles virus, rubella virus, and mumps virus in serum samples and in microquantities of whole blood dried on filter paper

Stability of human immunodeficiency virus type 1 antibodies in whole blood dried on filter paper and stored under various tropical conditions in Kinshasa, Zaire

Dried blood spots-preparing and processing for use in immunoassays and in molecular techniques

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Site-specific glycan analysis of the SARS-CoV-2 spike

High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay

Can dried blood spots (DBS) contribute to conducting comprehensive SARS-CoV-2 antibody tests? Drug Test Anal

Covid-19: risk factors for severe disease and death

We would like to thank the University of Birmingham Clinical Immunology Service for their invaluable support in sample collection and processing. We also thank Cynthia D'Aguilar and Julie Williams for logistic support in sample collection. We are grateful for the expertise of Margaret Goodall in generating the mouse monoclonal anti-human horseradish peroxidase conjugated antibodies. 

Dr. Morley is a clinician specializing in public health, currently undertaking her PhD research, which is focused on humoral immunology, at the University of Birmingham. She worked on SARS-CoV-2 diagnostics and research during the COVID-19 pandemic at the University of Birmingham.